Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.32 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31005440 | 1.00 | HDAC1 (0.39) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL9926762 | 0.84 | HDAC1 (0.39) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL574827 | 0.82 | HDAC1 (0.37) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL29353376 | 0.82 | HDAC1 (0.37) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL18726574 | 0.82 | HDAC1 (0.37) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL13632151 | 0.82 | HDAC1 (0.43) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL9904994 | 0.80 | HDAC1 (0.36) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL1120030 | 0.79 | ALDH1A1 (0.43) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL31005446 | 0.79 | ALDH1A1 (0.43) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL27076397 | 0.78 | HDAC1 (0.37) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046762-B2 | Cross-linkers and their uses | IMMUNOGEN, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046762-B2 | Cross-linkers and their uses | IMMUNOGEN, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200148764-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20200148764-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20180291100-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN SWITZERLAND GMBH (CH) | 2018-10-11 | — | — | US | disclosed |
| EP-3266469-A2 | CROSS-LINKERS AND THEIR USES | ImmunoGen, Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| EP-2281006-B1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20170157264-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170157264-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170157264-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20120282282-A1 | Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates | IMMUNOGEN, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120282282-A1 | Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates | IMMUNOGEN, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120282282-A1 | Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates | IMMUNOGEN, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-8236319-B2 | Cross-linkers and their uses | IMMUNOGEN, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236319-B2 | Cross-linkers and their uses | IMMUNOGEN, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236319-B2 | Cross-linkers and their uses | IMMUNOGEN, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| WO-2009134977-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090274713-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090274713-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090274713-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274713-A1 | CROSS-LINKERS AND THEIR USES | MTCL3, DCLRE1A, PCNA | HDAC1 228/4885HDAC2 387/4885LMNA 394/4885 |
| US-20180291100-A1 | CROSS-LINKERS AND THEIR USES | MTCL3, DCLRE1A, PCNA | HDAC1 228/4885HDAC2 387/4885LMNA 394/4885 |
| US-20120282282-A1 | Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates | UACA, CYTH3, FCGR2A | HDAC1 857/4885HDAC2 667/4885LMNA 614/4885 |
| US-20200148764-A1 | CROSS-LINKERS AND THEIR USES | MTCL3, DCLRE1A, PCNA | HDAC1 228/4885HDAC2 387/4885LMNA 394/4885 |
| US-20170157264-A1 | CROSS-LINKERS AND THEIR USES | MTCL3, DCLRE1A, PCNA | HDAC1 228/4885HDAC2 387/4885LMNA 394/4885 |
| US-11046762-B2 | Cross-linkers and their uses | MTCL3, DCLRE1A, PCNA | HDAC1 228/4885HDAC2 387/4885LMNA 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.